AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2115892
Drug: Pimozide (2-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (2-18 mg)
Trial: 2115892
Drug: Haloperidol (2-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2-15 mg)
Trial: 345410
Drug: Metronidazole 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1,000 mg daily for two months
Trial: 29394971
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and weight-bearing exercises
Trial: 22918094
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 to 0.75 mg/kg)
Trial: 22918094
Drug: Oral triclofos
RxNorm normalized name: Triclofos
DrugBank: Triclofos (DB06753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral triclofos
Trial: 22918094
Drug: Oral zolpidem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zolpidem
Trial: 20063224
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid group (lactated ringers at 250 ml per hour)
Trial: 17655695
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) + HBV vaccine (40 mug HBV(vac) after 5 mug/kg GM-CSF injection)
Trial: 17655695
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine (40 mug HBV(vac) intramuscularly)
Trial: 8819183
Drug: Propranolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (400 mg)
Trial: 7295883
Drug: Betamethasone tablet
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone tablet formulation A (2 mg)
Trial: 7295883
Drug: Betamethasone tablet
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone tablet formulation B (2 mg)
Trial: 7295883
Drug: Betamethasone phosphate
RxNorm normalized name: Betamethasone phosphate
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone phosphate solution C (2 mg)
Trial: 10445557
Drug: alpha-interferon (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-interferon (5 MU/m2 three times weekly for 6 months)
Trial: 8695970
Drug: MFP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day
Trial: 8695970
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day of oral calcium
Trial: 2392980
Drug: Beta 1-selective
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-selective beta blocker (metoprolol)
Trial: 2392980
Drug: Beta 1-nonselective
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-nonselective beta blocker (propranolol)
Trial: 7308268
Drug: muzolimine 240
RxNorm normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine 240 mg
Trial: 7308268
Drug: furosemide 240
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: furosemide 240 mg
Trial: 30117129
Drug: Eldecalcitol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol 0.75 μg
Trial: 31087185
Drug: Alfacalcidol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 1.0 μg
Trial: 16686722
Drug: Solifenacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (10 mg)
Trial: 28050642
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (60 mg)
Trial: 22136279
Drug: Chungkookjang (CKJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chungkookjang (CKJ) pills, 35 g per day for 3 months
Trial: 22136279
Drug: Placebo pills,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills, 35 g per day for 3 months
Trial: 22136279
Drug: Chungkookjang (CKJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chungkookjang (CKJ) pills
Trial: 18801775
Drug: Different footwear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different footwear types (air/gel/spring)
Trial: 16961791
Drug: Balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced amino acid condition (L-tryptophan present)
Trial: 16961791
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion condition (L-tryptophan omitted)
Trial: 15242999
Drug: Laparoscopic electrocautery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic electrocautery of the ovaries followed by CC and recombinant FSH (rFSH)
Trial: 8969629
Drug: Intravenous disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous disodium EDTA (3 g)
Trial: 1534639
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine stored at 4 degrees C
Trial: 1534639
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine heated for 1 week at 45 degrees C
Trial: 1534639
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine heated for 1 month at 37 degrees C
Trial: 3975851
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (doxorubicin, cyclophosphamide, and high-dose methotrexate)
Trial: 3975851
Drug: Chemotherapy (among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (among entire cohort)
Trial: 30865144
Drug: Another infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another infant physical therapy
Trial: 28096005
Drug: Lullaby group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lullaby group (n=26) listened to male lullaby via headphones for 20 minutes daily over 3 days
Trial: 9205924
Drug: Resorbable barrier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resorbable barrier in combination with decalcified freeze-dried bone allograft (DFDBA)
Trial: 9205924
Drug: Non-smokers in
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-smokers in both treatment groups
Trial: 3111785
Drug: Levonorgestrel 20
RxNorm normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 20 mcg/day IUD (LNg20)
Trial: 26149244
Drug: Cabozantinib (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (140 mg/day, with dose modifications allowed)
Trial: 24185158
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention to increase medication adherence
Trial: 14700452
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release (SR)
Trial: 14700452
Drug: Immediate-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulations
Trial: 11202895
Drug: 5% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% chlorhexidine gel
Trial: 1483292
Drug: Nafarelin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin and norethisterone 0.7 mg
Trial: 1483292
Drug: Nafarelin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin and norethisterone 1.4 mg
Trial: 1483292
Drug: Nafarelin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin and norethisterone 2.45 mg
Trial: 2996342
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (hydrochlorothiazide, timolol, and hydralazine)
Trial: 22247480
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (3 ng/kg per minute for 1 hour) in patients with POTS
Trial: 20193079
Drug: GSK256066 87.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256066 87.5 mcg once per day
Trial: 18095949
Drug: Tissue angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue angiotensin-converting enzyme (ACE) inhibitors
Trial: 12823383
Drug: Lifestyle and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle and behavioural interventions (e.g., education about the prostate and bladder, avoiding caffeine, urethral milking, reassurance about prostate cancer)
Trial: 11324900
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1 mg per day
Trial: 8467027
Drug: endotracheally administered
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endotracheally administered tobramycin
Trial: 2870533
Drug: dihomo‐gammalinolenic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihomo‐gammalinolenic acid (DHLA) with depot neuroleptic medication
Trial: 2870533
Drug: placebo depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo depot medication and DHLA capsules
Trial: 2870533
Drug: placebo depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo depot medication and placebo capsules
Trial: 27358262
Drug: Nefopam 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 2.4 mg/ml plus fentanyl 25 µg/ml (NF group)
Trial: 27358262
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 µg/ml (SF group)
Trial: 23078878
Drug: Reformulated inactivated
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health), administered as a 2.0 ml dose at 21 days of age.
Trial: 18669816
Drug: Subcutaneous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous etanercept (25 mg) twice weekly
Trial: 16433194
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg i.v. once daily for 1-4 days followed by azithromycin 500 mg orally once daily for 3 days
Trial: 16433194
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g i.v. three times daily for 1-4 days followed by cefuroxime axetil 500 mg orally twice daily for 7 days
Trial: 12939210
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=151)
Trial: 12092741
Drug: Roxifiban (0.75-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (0.75-1.5 mg; n = 20)
Trial: 12092741
Drug: Roxifiban (0.75-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (0.75-1.0 mg; n = 8)
Trial: 12092741
Drug: Roxifiban (0.5-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (0.5-0.75 mg; n = 8)
Trial: 12092741
Drug: Roxifiban (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (1.5 or 1.0 mg loading dose with or without 325 mg aspirin; n = 16)
Trial: 12092741
Drug: Roxifiban (1.25-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (1.25-1.5 mg)
Trial: 12092741
Drug: Roxifiban (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban (various doses)
Trial: 12092741
Drug: Roxifiban with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxifiban with aspirin pretreatment
Trial: 10449977
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN; n = 32)
Trial: 28759129
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity intervention (60 minutes daily for two school years)
Trial: 28759129
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (curriculum-defined physical education, 45 minutes twice a week)
Trial: 23013506
Drug: 2‐mL glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐mL glass tubes
Trial: 23013506
Drug: 2‐mL plastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐mL plastic tubes
Trial: 23013506
Drug: 3‐mL plastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mL plastic tubes
Trial: 23013506
Drug: 4‐mL plastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐mL plastic tubes
Trial: 23013506
Drug: 6‐mL plastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mL plastic tubes
Trial: 23013506
Drug: 10‐mL glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mL glass tubes
Trial: 23013506
Drug: 10‐mL plastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mL plastic tubes
Trial: 20519876
Drug: Oral bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bosentan
Trial: 17118684
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg plus fluticasone 250 microg twice daily
Trial: 15660766
Drug: Zonisamide 100
RxNorm normalized name: zonisamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 100 mg/day
Trial: 11004033
Drug: 300-microg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-microg oral clonidine premedication (n = 18)
Trial: 1428380
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g L-Tryptophan (L-TRY) supplementation
Trial: 30043572
Drug: Intranasal‐jejunum nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal‐jejunum nutrient canal placement using clamping pliers under gastroscope guidance
Trial: 30043572
Drug: Intranasal‐jejunum nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal‐jejunum nutrient canal placement using guide wire under gastroscope guidance
Trial: 24788875
Drug: Mobic (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobic (original product) 4 x 7.5 mg tablets
Trial: 24788875
Drug: Melocam (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melocam (generic product) 4 x 7.5 mg tablets
Trial: 23110267
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream (pain group)
Trial: 23110267
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (control group)
Trial: 18450339
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in phase II prophylactic HIV vaccine trials
Trial: 15657223
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg thrice daily)
Trial: 15657223
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual drug treatment)
Trial: 12819912
Drug: Epirubicin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 25 mg/m² (Epi25) on a weekly intravenous regimen
Trial: 12819912
Drug: Epirubicin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 100 mg/m² (Epi100) on a 4-weekly regimen
Trial: 25701454
Drug: Axitinib titration
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib titration (5 mg twice daily during lead-in, followed by stepwise dose increases)
Trial: 24140184
Drug: Axitinib titration
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib titration
Trial: 18252692
Drug: azithromycin-ER (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin-ER (2 g single oral dose)
Trial: 18252692
Drug: azithromycin-IR (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin-IR (500 mg single oral dose)
Trial: 8925582
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine hydrochloride (5.6 to 12.6 g/d)
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) at doses of 10, 20, or 40 mg/kg administered by 30-minute drip infusion.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) at doses of 10 to 20 mg/kg/once, 2 to 3 times a day, maximum dose 173 mg/kg/day q.i.d.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Staphylococcus aureus.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Streptococcus pneumoniae.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Gram-positive bacteria.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Gram-negative bacteria.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Haemophilus influenzae.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Pseudomonas aeruginosa.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Escherichia coli.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment for Klebsiella pneumoniae.
Trial: 1507401
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) treatment in cases with previous unsuccessful antibiotic therapies.
Trial: 23225026
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human epidermal growth factor (rhEGF) oral spray
Trial: 23028263
Drug: Ready-to-use supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use supplementary food (RUSF) 46 g daily for 4 months
Trial: 17761356
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil topical foam (MTF)
Trial: 15090413
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost 0.005% once daily for an average duration of 11 months
Trial: 11795452
Drug: Microwave treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwave treatment (maxillary denture microwaved for one minute at 850 Watts, repeated three times)
Trial: 11795452
Drug: Control (denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (denture soak treatment in 0.2% chlorhexidine digluconate solution overnight for 14 days)
Trial: 11795452
Drug: Control (denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (denture soak treatment)
Trial: 488520
Drug: Piracetam 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 2400 mg daily
Trial: 21806694
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (placebo pill)
Trial: 19338543
Drug: BoNT‐A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injections (200 U or 100 U) followed by hydrodistention (HD)
Trial: 16688845
Drug: Early removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early removal of nasogastric tube and early oral feeding (experimental group, n=161)
Trial: 11775047
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Ginkgo biloba (EGb) plus haloperidol (0.25 mg/kg/day)
Trial: 11775047
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus haloperidol (0.25 mg/kg/day)